Sun Pharma Acquires a US Company

In a landmark move for India’s pharmaceutical sector, Sun Pharmaceutical Industries has announced the acquisition of US-based healthcare major Organon & Co.. The deal, valued at $11.75 billion (over ₹1.10 lakh crore), will be executed entirely in cash, making it one of the largest overseas acquisitions by an Indian corporate and the biggest deal in the domestic pharma industry. As per the agreement, Sun Pharma will pay $14 per share of Organon, with both companies’ boards already approving the transaction.

The deal is expected to be completed by 2027, subject to regulatory clearances and approval from Organon’s shareholders. To finance the acquisition, Sun Pharma plans to utilize its cash reserves of $2–2.5 billion and raise additional debt of $9.25–9.75 billion from banks. This strategic move is anticipated to significantly strengthen Sun Pharma’s global footprint and expand its presence in the international healthcare market.